The Aurum Institute Klerksdorp Clinical Research Centre
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Innes, James C
NCT05118490: Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Recruiting
4
1000
RoW
Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks
The Aurum Institute NPC, Johns Hopkins University
HIV Seropositivity, Tuberculosis, Household Contact
10/24
12/24
Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting
3b
500000
RoW
Booster vaccine
Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine
SARS CoV 2 Infection
01/22
06/23
CoTeT, NCT05459532: A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa

Recruiting
3
4000
RoW
Molnupiravir 200 mg
University of Witwatersrand, South Africa, Bill and Melinda Gates Foundation
COVID-19
07/24
07/27
REVIVE, NCT05580666: Reducing Mortality in Adults With Advanced HIV Disease

Recruiting
3
8000
RoW
Azithromycin Oral Tablet, Placebo oral tablet
Population Health Research Institute
HIV Disease Progression
05/28
08/28
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24

Download Options